(:CSII)

Apr 25, 2023 05:54 pm ET
Cytek Biosciences Set to Join S&P SmallCap 600
NEW YORK, April 25, 2023 /PRNewswire/ -- Cytek Biosciences Inc (NASD:CTKB) will replace Cardiovascular Systems Inc. (NASD:CSII) in the S&P SmallCap 600 effective prior to the opening of trading on Monday, May 1. S&P 500 and 100 constituent Abbott Laboratories (NYSE:ABT) is acquiring Cardiovascular Systems in a deal expected to be completed soon, pending final closing conditions.
Apr 13, 2023 12:49 pm ET
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates CSII, NUVA, OSH, SUMO
Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: Cardiovascular Systems, Inc. (NASDAQ:...
Apr 12, 2023 05:20 pm ET
SHAREHOLDER ALERT: The M&A Class Action Firm Continues its Investigation of the Merger – ANGN, FOCS, UNVR, CSII
Juan Monteverde, founder and managing partner of the class action firm Monteverde & Associates PC (the “M&A Class Action Firm”), a national securities firm rated Top 50 in the 2018-2021 ISS Securities Class Action Services Report and headquartered...
Apr 11, 2023 01:42 pm ET
SHAREHOLDER UPDATE: Halper Sadeh LLC Investigates CSII, ANGN, OSH, NUVA
NEW YORK, April 11, 2023 /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to:
Apr 06, 2023 11:35 am ET
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates CSII, NUVA, OSH, MAXR
NEW YORK, April 6, 2023 /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to:
Apr 05, 2023 04:00 pm ET
SHAREHOLDER ALERT: The M&A Class Action Firm Continues its Investigation of the Merger – NUVA, CSII, ANGN, AGFS
Juan Monteverde, founder and managing partner of the class action firm Monteverde & Associates PC (the “M&A Class Action Firm”), a national securities firm rated Top 50 in the 2018-2021 ISS Securities Class Action Services Report and headquartered...
Apr 03, 2023 04:05 pm ET
Cardiovascular Systems, Inc. Completes Enrollment of ECLIPSE Clinical Trial
Cardiovascular Systems, Inc. (CSI) (NASDAQ: CSII), a medical device company developing and commercializing innovative interventional treatment systems for patients with peripheral and coronary artery disease, announced today the company completed the enrollment of its 2,000 patient ECLIPSE coronary trial.
Mar 30, 2023 09:28 am ET
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates CSII, TIG, MPB, ANGN
Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: Cardiovascular Systems, Inc. (NASDAQ:...
Mar 29, 2023 04:35 pm ET
ALERT: The M&A Class Action Firm Continues its Investigation of the Merger – ANGN, CSII, AGFS, NUVA
Juan Monteverde, founder and managing partner of the class action firm Monteverde & Associates PC (the “M&A Class Action Firm”), a national securities firm rated Top 50 in the 2018-2021 ISS Securities Class Action Services Report and headquartered...
Mar 29, 2023 03:14 pm ET
CARDIOVASCULAR SYSTEMS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Cardiovascular Systems, Inc. -
Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Cardiovascular Systems, Inc. (“CSI”) (NasdaqGS: CSII) to Abbott Laboratories (NYSE: ABT). Under the terms of the proposed transaction, shareholders of CSI will receive $20.00 in cash for each share of CSI that they own. KSF is seeking to determine whether this consideration and the process that led to it are adequate, or whether the consideration undervalues the Company.
Mar 28, 2023 11:50 am ET
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates CSII, NUVA, SUMO, OSH
NEW YORK, March 28, 2023 /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to:
Mar 24, 2023 09:02 am ET
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates ANGN, CSII, MPB, TIG
Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: Angion Biomedica Corp. (NASDAQ:...
Mar 23, 2023 03:04 pm ET
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates CSII, ARGO, SUMO, NUVA
NEW YORK, March 23, 2023 /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to:
Mar 22, 2023 03:50 pm ET
STOCKHOLDER ALERT: The M&A Class Action Firm Continues its Investigation of the Merger – NUVA, ANGN, AGFS, CSII
Juan Monteverde, founder and managing partner of the class action firm Monteverde & Associates PC (the “M&A Class Action Firm”), a national securities firm rated Top 50 in the 2018-2021 ISS Securities Class Action Services Report and headquartered...
Mar 16, 2023 09:08 am ET
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates ANGN, CSII, NUVA
Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: Angion Biomedica Corp. (NASDAQ:...
Mar 15, 2023 05:14 pm ET
SHAREHOLDER ALERT: The M&A Class Action Firm Continues its Investigation of the Merger – AGFS, NUVA, CSII, ANGN
Juan Monteverde, founder and managing partner of the class action firm Monteverde & Associates PC (the “M&A Class Action Firm”), a national securities firm rated Top 50 in the 2018-2021 ISS Securities Class Action Services Report and...
Mar 14, 2023 11:55 am ET
SHAREHOLDER NOTICE: Halper Sadeh LLC Investigates CSII, NUVA, SUMO
NEW YORK, March 14, 2023 /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to:
Mar 01, 2023 04:17 pm ET
ALERT: The M&A Class Action Firm Continues its Investigation of the Merger – TIG, NBTB, CSII, MPB
Juan Monteverde, founder and managing partner of the class action firm Monteverde & Associates PC (the “M&A Class Action Firm”), a national securities firm rated Top 50 in the 2018-2021 ISS Securities Class Action Services Report and headquartered...
Feb 28, 2023 09:04 am ET
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates BRMK, FOCS, CSII, TIG
Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: Broadmark Realty Capital Inc. (NYSE:...
Feb 22, 2023 05:16 pm ET
ALERT: The M&A Class Action Firm Continues its Investigation of the Merger – NBTB, MPB, CSII, NUVA
Juan Monteverde, founder and managing partner of the class action firm Monteverde & Associates PC (the “M&A Class Action Firm”), a national securities firm rated Top 50 in the 2018-2021 ISS Securities Class Action Services Report and headquartered...
Feb 22, 2023 10:33 am ET
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: NUVASIVE (Nasdaq – NUVA), Oak Street Health (NYSE – OSH), Argo Group International Holdings, Ltd. (NYSE - ARGO)
Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky ([email protected]) or Marc Ackerman ([email protected]) at 855-576-4847. There is no...
Feb 19, 2023 08:34 am ET
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates CSII, NUVA, ALR
Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: Cardiovascular Systems, Inc. (NASDAQ:...
Feb 17, 2023 08:00 pm ET
STOCKHOLDER ALERT: The M&A Class Action Firm Continues its Investigation of the Merger – SUMO, CSII, NUVA, FMIA
Juan Monteverde, founder and managing partner of the class action firm Monteverde & Associates PC (the “M&A Class Action Firm”), a national securities firm rated Top 50 in the 2018-2021 ISS Securities Class Action Services Report and headquartered...
Feb 16, 2023 09:46 am ET
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates OSH, ARGO, CSII
NEW YORK, Feb. 16, 2023 /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to:
Feb 14, 2023 01:39 pm ET
Moore Kuehn Encourages ARGO, OSH, CSII, and NUVA Investors to Contact Law Firm
Moore Kuehn, PLLC, a law firm focusing in securities litigation located on Wall Street in downtown New York City, is investigating potential claims concerning whether the following proposed mergers are fair to shareholders. Moore Kuehn may seek...
Feb 14, 2023 11:04 am ET
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: NUVASIVE (Nasdaq – NUVA), Oak Street Health (NYSE – OSH), Argo Group International Holdings, Ltd. (NYSE - ARGO)
Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky ([email protected]) or Marc Ackerman ([email protected]) at 855-576-4847. There is no...
Feb 13, 2023 06:41 pm ET
SHAREHOLDER ALERT: The M&A Class Action Firm Announces the Investigation of Cardiovascular Systems, Inc. - CSII
NEW YORK, Feb. 13, 2023 /PRNewswire/ -- Juan Monteverde, founder and managing partner of the class action firm Monteverde & Associates PC (the "M&A Class Action Firm"), a national securities firm rated Top 50 in the 2018-2021 ISS Securities Class Action Services Report and headquartered at the Empire State Building in New York City, is investigating Cardiovascular Systems, Inc. (NASDAQ: CSII), relating to its proposed sale to Abbott Laboratories. Under the terms of the agreement, CSII shareholders are expected to receive $20.00 in cash per common share they own. Click here for more i
Feb 13, 2023 10:48 am ET
CARDIOVASCULAR SYSTEMS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Cardiovascular Systems, Inc. -
Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Cardiovascular Systems, Inc. (“CSI”) (NasdaqGS: CSII) to Abbott Laboratories (NYSE: ABT). Under the terms of the proposed transaction, shareholders of CSI will receive $20.00 in cash for each share of CSI that they own. KSF is seeking to determine whether this consideration and the process that led to it are adequate, or whether the consideration undervalues the Company.
Feb 11, 2023 10:37 pm ET
Moore Kuehn Encourages OSH, NUVA, CSII, and ARGO Investors to Contact Law Firm
NEW YORK, Feb. 11, 2023 /PRNewswire/ -- Moore Kuehn, PLLC, a law firm focusing in securities litigation located on Wall Street in downtown New York City, is investigating potential claims concerning whether the following proposed mergers are fair to shareholders. Moore Kuehn may seek increased consideration, additional disclosures, or other relief on behalf of the shareholders of these companies:
Feb 11, 2023 08:11 pm ET
Lifshitz Law PLLC Announces Investigations of SUMO, GMED, NUVA, and CSII
Sumo Logic, Inc. (NASDAQ: SUMO) Lifshitz Law PLLC announces an investigation into possible breach of fiduciary duties in connection with the sale of SUMO to affiliates of Francisco Partners for $12.05 per share in cash. If you are a SUMO...
Feb 10, 2023 06:24 am ET
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates OSH, ARGO, CSII
Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: Oak Street Health, Inc. (NYSE:...
Feb 09, 2023 06:31 pm ET
SHAREHOLDER ALERT: Weiss Law Investigates Cardiovascular Systems, Inc.
NEW YORK, Feb. 9, 2023 /PRNewswire/ -- Weiss Law is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Cardiovascular Systems, Inc. ("Cardiovascular Systems" or the "Company") (NASDAQ: CSII), in connection with the proposed acquisition of the Company by Abbott Laboratories (NYSE: ABT). Under the terms of the merger agreement, the Company's shareholders will receive $20.00 in cash for each share of Cardiovascular Systems owned. The transaction is valued at approximately $890 million. 
Feb 09, 2023 09:30 am ET
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates OSH, ARGO, CSII
NEW YORK, Feb. 9, 2023 /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to:
Feb 09, 2023 09:29 am ET
CSII Alert: Monsey Law Firm of Wohl & Fruchter LLP Investigating Sale of Cardiovascular Systems, Inc. to Abbott Laboratories
The law firm of Wohl & Fruchter LLP is investigating whether the directors of Cardiovascular Systems, Inc. (Nasdaq: CSII) (“CSII”) acted in the best interests of CSII shareholders in approving the sale of CSII to Abbott Laboratories (“Abbott”) for...
Feb 09, 2023 09:08 am ET
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: NUVASIVE (Nasdaq – NUVA), Oak Street Health (NYSE – OSH), Argo Group International Holdings, Ltd. (NYSE - ARGO)
Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky ([email protected]) or Marc Ackerman ([email protected]) at 855-576-4847. There is no...
Feb 09, 2023 07:13 am ET
CSII STOCK ALERT: Halper Sadeh LLC Is Investigating Whether the Sale of Cardiovascular Systems, Inc. Is Fair to Shareholders
Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Cardiovascular Systems, Inc. (NASDAQ: CSII) to Abbott Laboratories for $20.00 per common share is fair to Cardiovascular shareholders.
Feb 08, 2023 06:12 pm ET
Cardiovascular Systems, Inc. Reports Fiscal 2023 Second Quarter Financial Results
Cardiovascular Systems, Inc. (CSI®) (NASDAQ: CSII), a medical device company developing and commercializing innovative interventional treatment systems for patients with peripheral and coronary artery disease, today reported financial results for its second quarter, ended December 31, 2022.
Jan 19, 2023 07:00 am ET
Cardiovascular Systems, Inc. to Host Earnings Conference Call on February 9, 2023
Cardiovascular Systems, Inc. (NASDAQ: CSII) plans to announce its operating results for the quarter ended December 31, 2022 before the market opens on Thursday, February 9, 2023, and will host a conference call at 9:00 a.m. ET that day to discuss those results.
Jan 11, 2023 04:05 pm ET
Cardiovascular Systems, Inc. Enrolls First Patient in Japan for Kaizen Clinical Study
Cardiovascular Systems, Inc. (CSI) (NASDAQ: CSII), a medical device company developing and commercializing innovative interventional treatment systems for patients with peripheral and coronary artery disease, announced today the company has initiated the KAIZEN clinical study of its Diamondback 360© Peripheral Orbital Atherectomy System (OAS) for the treatment of calcified plaque in patients with peripheral artery disease (PAD). The study is intended to support regulatory approval in Japan.
Jan 04, 2023 04:05 pm ET
Cardiovascular Systems, Inc. Announces FDA 510(k) Submission of Innova Vascular, Inc.’s Thrombectomy System
Cardiovascular Systems, Inc. (CSI®) (NASDAQ: CSII), a medical device company developing and commercializing innovative interventional treatment systems for patients with peripheral and coronary artery disease, announced today that Innova Vascular, Inc. (Innova) has submitted a 510(k) Premarket Notification to the U.S. Food and Drug Administration (FDA) for its thrombectomy devices intended to treat peripheral vascular disease.
Nov 09, 2022 04:05 pm ET
Cardiovascular Systems, Inc. to Participate in Two November Healthcare Conferences
Cardiovascular Systems, Inc. (CSI®) (NASDAQ: CSII), a medical device company developing and commercializing innovative interventional treatment systems for patients with peripheral and coronary artery disease, today announced that management plans to present and host investor meetings at the Stifel 2022 Healthcare Conference and will host investor meetings at the Canaccord Genuity MedTech Conference.
Nov 03, 2022 07:00 am ET
Cardiovascular Systems, Inc. Reports Fiscal 2023 First Quarter Financial Results
Cardiovascular Systems, Inc. (CSI®) (NASDAQ: CSII), a medical device company developing and commercializing innovative interventional treatment systems for patients with peripheral and coronary artery disease, today reported financial results for its first quarter, ended September 30, 2022.
Oct 17, 2022 07:00 am ET
Cardiovascular Systems, Inc. Announces Full Market Release of the 2.00 Max Crown for Peripheral Orbital Atherectomy Systems
Cardiovascular Systems, Inc. (CSI) (NASDAQ: CSII), a medical device company developing and commercializing innovative interventional treatment systems for patients with peripheral and coronary artery disease, announced today the full market release of the 2.00 Max Crown for Peripheral Orbital Atherectomy Systems (2.00 Max Crown).
Oct 12, 2022 07:00 am ET
Cardiovascular Systems, Inc. to Host Earnings Conference Call on November 3, 2022
Cardiovascular Systems, Inc. (CSI®) (NASDAQ: CSII) plans to announce its operating results for the quarter ended September 30, 2022 before the market opens on Thursday, November 3, 2022, and will host a conference call at 8:00 a.m. CT (9:00 a.m. ET) that day to discuss those results.
Aug 02, 2022 08:30 pm ET
Cardiovascular Systems, Inc. Reports Fiscal 2022 Fourth Quarter and Full Year Financial Results
Cardiovascular Systems, Inc. (CSI®) (NASDAQ: CSII), a medical device company developing and commercializing innovative interventional treatment systems for patients with vascular and coronary artery disease, today reported financial results for its fourth quarter and full year, ended June 30, 2022.
Jul 13, 2022 07:00 am ET
Cardiovascular Systems, Inc. to Release Fiscal 2022 Fourth Quarter Results on August 2, 2022
Cardiovascular Systems, Inc. (CSI®) (NASDAQ: CSII) will release fourth-quarter results the evening of August 2. In lieu of hosting a quarterly earnings conference call, CSI management will discuss fourth-quarter results at the beginning of its capital markets day on August 3. The webcast of the capital markets day will begin on Wednesday, August 3, 2022, at 9:00 a.m. CT (10:00 a.m. ET).
May 04, 2022 07:00 am ET
Cardiovascular Systems, Inc. Reports Fiscal 2022 Third Quarter Financial Results
Cardiovascular Systems, Inc. (CSI®) (NASDAQ: CSII), a medical device company developing and commercializing innovative interventional treatment systems for patients with peripheral and coronary artery disease, today reported financial results for its third quarter, ended March 31, 2022.
Apr 13, 2022 07:00 am ET
Cardiovascular Systems, Inc. to Host Earnings Conference Call on May 4, 2022
Cardiovascular Systems, Inc. (CSI®) (NASDAQ: CSII) plans to announce its operating results for the quarter ended March 31, 2022 before the market opens on Wednesday, May 4, 2022, and will host a conference call at 8:00 a.m. CT (9:00 a.m. ET) that day to discuss those results.
Mar 22, 2022 10:57 am ET
Cardiovascular Systems, Inc. to Participate at Two Upcoming Healthcare Conferences
Cardiovascular Systems, Inc. (CSI®) (NASDAQ: CSII), a medical device company developing and commercializing innovative interventional treatment systems for patients with peripheral and coronary artery disease, today announced that management plans to present and host investor meetings at two upcoming healthcare conferences. Live webcasts and replays of the presentations will be available on the investor relations section of the corporate website.
Mar 16, 2022 09:32 am ET
Cardiovascular Systems, Inc. Announces First In-Human Experience With Company’s Propel™ Percutaneous Ventricular Assist Device
Cardiovascular Systems, Inc. (CSI®) (NASDAQ: CSII), a medical device company developing and commercializing innovative interventional treatment systems for patients with peripheral and coronary artery disease, announced today the first in-human experience with Propel™, its first-generation percutaneous ventricular assist device (pVAD), offering hemodynamic support for patients undergoing high-risk percutaneous coronary interventions (HR-PCI).
Mar 09, 2022 07:00 am ET
Cardiovascular Systems, Inc. Announces First In-Human Experience With Peripheral Everolimus Drug-Coated Balloon
Cardiovascular Systems, Inc. (CSI®) (NASDAQ: CSII), a medical device company developing and commercializing innovative interventional treatment systems for patients with peripheral and coronary artery disease, announced today the start of enrollment in a first in-human trial of the peripheral everolimus drug-coated balloon (DCB) being developed by Chansu Vascular Technologies, LLC (CVT).
Mar 04, 2022 07:00 am ET
Cardiovascular Systems, Inc. Appoints Jeffery W. Chambers, M.D., as Chief Medical Officer
Cardiovascular Systems, Inc. (CSI) (NASDAQ: CSII), a medical device company developing and commercializing innovative interventional treatment systems for peripheral and coronary vascular disease, today announced that it has appointed Jeffery W. Chambers, M.D., as Chief Medical Officer.
Feb 23, 2022 07:00 am ET
Cardiovascular Systems, Inc. Announces Partnership With Innova Vascular, Inc. to Develop Full Line of Thrombectomy Devices
Cardiovascular Systems, Inc. (CSI®) (NASDAQ: CSII), a medical device company developing and commercializing innovative interventional treatment systems for patients with peripheral and coronary artery disease, announced today it has partnered with Innova Vascular, Inc. (Innova) to develop a full line of novel thrombectomy devices.
Feb 03, 2022 06:00 am ET
Cardiovascular Systems, Inc. Reports Fiscal 2022 Second Quarter Financial Results
Cardiovascular Systems, Inc. (CSI®) (NASDAQ: CSII), a medical device company developing and commercializing innovative interventional treatment systems for patients with peripheral and coronary artery disease, today reported financial results for its second quarter, ended December 31, 2021.
Jan 27, 2022 07:00 am ET
Cardiovascular Systems, Inc. to Participate at SVB Leerink 2022 Global Healthcare Conference
Cardiovascular Systems, Inc. (CSI®) (NASDAQ: CSII), a medical device company developing and commercializing innovative interventional treatment systems for patients with peripheral and coronary artery disease, today announced that management plans to present and host investor meetings at the SVB Leerink 2022 Global Healthcare Conference on February 18th. A webcast of the presentation will be made available
Jan 20, 2022 07:00 am ET
Cardiovascular Systems, Inc. and OrbusNeich Announce FDA PMA Approval of Scoreflex® Scoring Balloon
Cardiovascular Systems, Inc. (CSI®) (NASDAQ: CSII), a medical device company developing and commercializing innovative interventional treatment systems for patients with peripheral and coronary artery disease, today, along with OrbusNeich Medical Company Ltd (OrbusNeich®), announced FDA PMA approval of OrbusNeich’s Scoreflex® NC Scoring Percutaneous Transluminal Coronary Angioplasty (PTCA) Catheter (Scoreflex NC).
Jan 13, 2022 04:05 pm ET
Cardiovascular Systems, Inc. Announces Development of Intravascular Lithotripsy Technology for the Treatment of Coronary and Peripheral Artery Diseases
Cardiovascular Systems, Inc. (CSI®) (NASDAQ: CSII), a medical device company developing and commercializing innovative interventional treatment systems for patients with peripheral and coronary artery disease, announced today it has made significant progress towards the commercialization of intravascular lithotripsy (IVL) systems for the treatment of calcific coronary and peripheral artery disease.
Jan 06, 2022 10:48 am ET
CORRECTING and REPLACING Cardiovascular Systems, Inc. to Webcast Fiscal 2022 Second-Quarter Earnings Conference Call Thursday, February 3
In a press release issued under the same headline on January 6, by Cardiovascular Systems, Inc. (CSI ®) (NASDAQ: CSII), please note that the registration link to participate in the conference call was inaccurate.
Jan 06, 2022 07:00 am ET
Cardiovascular Systems, Inc. to Webcast Fiscal 2022 Second-Quarter Earnings Conference Call Thursday, February 3
Cardiovascular Systems, Inc. (CSI®) (NASDAQ: CSII) will host a live webcast of its fiscal 2022 second-quarter conference call on Thursday, February 3, 2022, at 8:00 a.m. CT (9:00 a.m. ET). CSI management will discuss results for its fiscal second quarter ended December 31, 2021, and its financial outlook. CSI will issue an earnings release prior to the call on February 3, 2022.
Nov 24, 2021 04:05 pm ET
Cardiovascular Systems, Inc. Initiates Voluntary Recall of WIRION® Embolic Protection System
Cardiovascular Systems, Inc. (CSI®) (NASDAQ: CSII) has initiated a voluntary recall of unused WIRION Embolic Protection Systems (WIRION) due to complaints of filter breakage during retrieval.
Nov 09, 2021 06:00 am ET
Cardiovascular Systems, Inc. Reports Fiscal 2022 First Quarter Financial Results
Cardiovascular Systems, Inc. (CSI®) (NASDAQ: CSII), a medical device company developing and commercializing innovative interventional treatment systems for patients with peripheral and coronary artery disease, today reported financial results for its fiscal first quarter, ended September 30, 2021.
Nov 04, 2021 01:00 pm ET
Cardiovascular Systems, Inc. Announces First In-Human Experience With Coronary Everolimus Drug Coated Balloon
Cardiovascular Systems, Inc. (CSI®) (NASDAQ: CSII), a medical device company developing and commercializing innovative interventional treatment systems for patients with peripheral and coronary artery disease, announced today the start of enrollment in a first in-human trial of the coronary everolimus drug-coated balloon (DCB) being developed by Chansu Vascular Technologies, LLC (CVT).
Nov 02, 2021 04:05 pm ET
Cardiovascular Systems, Inc. to Participate at the Stifel 2021 Virtual Healthcare Conference
Cardiovascular Systems, Inc. (CSI®) (NASDAQ: CSII), a medical device company developing and commercializing innovative interventional treatment systems for patients with peripheral and coronary artery disease, today announced that management plans to present and host investor meetings at the Stifel 2021 Virtual Healthcare Conference.
Oct 11, 2021 04:05 pm ET
Cardiovascular Systems, Inc. to Webcast Fiscal 2022 First-Quarter Earnings Conference Call Tuesday, November 9
Cardiovascular Systems, Inc. (CSI®) (NASDAQ: CSII) will host a live webcast of its fiscal 2022 first-quarter conference call on Tuesday, November 9, 2021, at 8:00 a.m. CT (9:00 a.m. ET). CSI management will discuss results for its fiscal first quarter ended September 30, 2021, and its financial outlook. CSI will issue an earnings release prior to the call on November 9, 2021.
Sep 29, 2021 04:40 pm ET
Cardiovascular Systems, Inc. Announces First Patient Treated with ViperCross™ Peripheral Support Catheter
Cardiovascular Systems, Inc. (CSI) (NASDAQ: CSII), a medical device company developing and commercializing innovative interventional treatment systems for patients with peripheral and coronary artery disease, announced today that the first patient has been successfully treated with its ViperCross peripheral support catheter.
Aug 30, 2021 04:05 pm ET
First Patients in Canada Treated With Cardiovascular Systems, Inc. Diamondback 360® Coronary Orbital Atherectomy System
Cardiovascular Systems, Inc. (CSI®) (NASDAQ: CSII), a medical device company developing and commercializing innovative interventional treatment systems for patients with peripheral and coronary artery disease, announced today that the first patients in Canada have been treated with its Diamondback 360® Coronary Orbital Atherectomy System (OAS).
Aug 04, 2021 04:05 pm ET
Cardiovascular Systems, Inc. Reports Fiscal 2021 Fourth Quarter and Full Year Financial Results
Executive Commentary – Scott Ward, Chairman, President and CEO
Jul 27, 2021 07:00 am ET
Cardiovascular Systems, Inc. to Attend Three Investor Conferences in August
Cardiovascular Systems, Inc. (CSI®) (NASDAQ: CSII), a medical device company developing and commercializing innovative interventional treatment systems for patients with peripheral and coronary artery disease, today announced that management plans to attend three investor conferences in August.
Jul 14, 2021 07:00 am ET
Cardiovascular Systems, Inc. to Webcast Fiscal 2021 Fourth-Quarter Earnings Conference Call Wednesday, August 4
Cardiovascular Systems, Inc. (CSI®) (NASDAQ: CSII) will host a live webcast of its fiscal 2021 fourth-quarter conference call on Wednesday, August 4, 2021, at 3:30 p.m. CT (4:30 p.m. ET). CSI management will discuss results for its fiscal fourth quarter ended June 30, 2021, and its financial outlook. CSI will issue a post-market earnings release prior to the call on August 4, 2021.
Jun 02, 2021 07:00 am ET
Cardiovascular Systems, Inc. to Participate at the Raymond James Human Health Innovations Conference
Cardiovascular Systems, Inc. (CSI®) (NASDAQ: CSII), a medical device company developing and commercializing innovative interventional treatment systems for patients with peripheral and coronary artery disease, today announced that management plans to present and host investor meetings at the Raymond James Human Health Innovations Conference on June 23rd. A webcast of the presentation will be made available on
Jun 01, 2021 07:00 am ET
Cardiovascular Systems, Inc. Announces U.S. Commercial Launch of JADE Over-the-Wire Non-Compliant Peripheral Balloon Catheters
Cardiovascular Systems, Inc. (CSI®) (NASDAQ: CSII), a medical device company developing and commercializing innovative interventional treatment systems for patients with peripheral and coronary artery disease, announced today that the full line of OrbusNeich® JADE® percutaneous transluminal angioplasty (PTA) over-the-wire (OTW) balloon catheters is now available in the U.S.
May 20, 2021 04:00 am ET
New Study Demonstrates Exceptional Performance With Cardiovascular Systems’ Diamondback 360® Coronary Orbital Atherectomy System (OAS) Dual Mode of Action
Cardiovascular Systems, Inc. (CSI®) (NASDAQ: CSII), a medical device company developing and commercializing innovative interventional treatment systems for patients with peripheral and coronary artery disease, announced today that results from a real-world optical coherence tomography (OCT) imaging study of coronary OAS patients were released at EuroPCR 2021.
May 06, 2021 04:05 pm ET
Cardiovascular Systems, Inc. Reports Fiscal 2021 Third-Quarter Financial Results
Cardiovascular Systems, Inc. (CSI®) (NASDAQ: CSII), a medical device company developing and commercializing innovative interventional treatment systems for patients with peripheral and coronary artery disease, today reported financial results for its fiscal third quarter, ended March 31, 2021.
May 03, 2021 04:05 pm ET
Journal of Medical Economics Article Demonstrates Economic Benefits of Cardiovascular Systems Orbital Atherectomy in the Treatment of Peripheral Artery Disease (PAD)
Cardiovascular Systems, Inc. (CSI®) (NASDAQ: CSII), a medical device company developing and commercializing innovative interventional treatment systems for patients with peripheral and coronary artery disease, today announced that a new article published in the Journal of Medical Economics reviews the two-year PAD-related health care costs of patients enrolled in the LIBERTY 360° trial.
Apr 27, 2021 07:00 am ET
Cardiovascular Systems, Inc. to Participate at BofA Securities 2021 Health Care Conference
Cardiovascular Systems, Inc. (CSI®) (NASDAQ: CSII), a medical device company developing and commercializing innovative interventional treatment systems for patients with peripheral and coronary artery disease, today announced that management plans to present and host investor meetings at the BofA Securities 2021 Health Care Conference on May 11th. A webcast of the presentation will be made available on
Apr 15, 2021 07:00 pm ET
Cardiovascular Systems, Inc. to Webcast Fiscal 2021 Third-Quarter Earnings Conference Call Thursday, May 6
Cardiovascular Systems, Inc. (CSI®) (NASDAQ: CSII) will host a live webcast of its fiscal 2021 third-quarter conference call on Thursday, May 6, 2021, at 3:30 p.m. CT (4:30 p.m. ET). CSI management will discuss results for its fiscal third quarter ended March 31, 2021, and its financial outlook. CSI will issue a post-market earnings release prior to the call on May 6, 2021.
Apr 08, 2021 07:00 am ET
Cardiovascular Systems, Inc. Announces Investment and Acquisition Option Agreement With Telehealth Company, CarePICS, LLC
Cardiovascular Systems, Inc. (CSI®) (NASDAQ: CSII) announced today that it has completed a minority investment and entered into an acquisition option agreement with CarePICS, LLC (CarePICS®), a telehealth company offering a virtual care platform designed to improve the outcomes of patients suffering from peripheral artery disease (PAD), critical limb ischemia (CLI) and lower extremity wounds.
Mar 24, 2021 07:00 am ET
Cardiovascular Systems, Inc. to Participate at the 20th Annual Needham Healthcare Conference
Cardiovascular Systems, Inc. (CSI®) (NASDAQ: CSII), a medical device company developing and commercializing innovative interventional treatment systems for patients with peripheral and coronary artery disease, today announced that management plans to present and host investor meetings at the 20th Annual Needham Healthcare conference on Tuesday, April 13, 2021. A webcast of the presentation will be made available on
Mar 22, 2021 09:00 am ET
Cardiovascular Systems, Inc. Announces Acquisition of Peripheral Support Catheters From WavePoint Medical, LLC
Cardiovascular Systems, Inc. (CSI®) (NASDAQ: CSII) announced today that it has acquired a line of peripheral support catheters from WavePoint Medical, LLC.
Mar 17, 2021 07:00 am ET
Cardiovascular Systems, Inc. Announces First Uses of WIRION® Embolic Protection System
Cardiovascular Systems, Inc. (CSI®) (NASDAQ: CSII), a medical device company developing and commercializing innovative interventional treatment systems for patients with peripheral and coronary artery disease, announced today that the first patients in the U.S. have been treated with the WIRION® Embolic Protection System.
Feb 11, 2021 07:00 am ET
Cardiovascular Systems, Inc. to Participate at Four Upcoming Investor Conferences
Cardiovascular Systems, Inc. (CSI®) (NASDAQ: CSII), a medical device company developing and commercializing innovative interventional treatment systems for patients with peripheral and coronary artery disease, today announced that management plans to present and host investor meetings at three upcoming conferences. Webcasts of each of the presentations will be made available on
Feb 08, 2021 04:05 pm ET
First Patient in Europe Treated With Cardiovascular Systems, Inc. Diamondback 360® Coronary Orbital Atherectomy System
Cardiovascular Systems, Inc. (CSI®) (NASDAQ: CSII), a medical device company developing and commercializing innovative interventional treatment systems for patients with peripheral and coronary artery disease, announced today that the first patient in Europe has been treated with its Diamondback 360® Coronary Orbital Atherectomy System (OAS).
Feb 03, 2021 04:05 pm ET
Cardiovascular Systems, Inc. Reports Fiscal 2021 Second-quarter Financial Results
Cardiovascular Systems, Inc. (CSI®) (NASDAQ: CSII), a medical device company developing and commercializing innovative interventional treatment systems for patients with peripheral and coronary artery disease, today reported financial results for its fiscal second quarter, ended December 31, 2020.
Feb 01, 2021 07:00 am ET
Cardiovascular Systems, Inc. Announces Partnership With Chansu Vascular Techologies, LLC to Develop New Drug-Coated Balloon Technology
Cardiovascular Systems, Inc. (CSI®) (NASDAQ: CSII) announced today that it has partnered with Chansu Vascular Technologies, LLC (CVT) to develop novel peripheral and coronary everolimus drug-coated balloons (DCBs). This partnership brings together CSI’s leadership in the treatment of calcified arterial lesions with Dr. Philippe Marco, a pioneer in the successful development of several drug-coated devices.
Jan 27, 2021 05:00 pm ET
Cardiovascular Systems, Inc. Announces Sachin H. Jain, MD, MBA, Joins Board of Directors
Cardiovascular Systems, Inc. (CSI®) (NASDAQ: CSII), a medical device company developing and commercializing innovative interventional treatment systems for patients with peripheral and coronary artery disease, today announced the addition of independent board member Sachin H. Jain, MD, MBA.
Jan 18, 2021 04:05 pm ET
Cardiovascular Systems, Inc. Receives CE Mark for Diamondback 360® Coronary Orbital Atherectomy System
Cardiovascular Systems, Inc. (CSI®) (NASDAQ: CSII), a medical device company developing and commercializing innovative interventional treatment systems for patients with peripheral and coronary artery disease, announced today that it has received CE Mark for its Diamondback 360® Coronary Orbital Atherectomy System (OAS) and ViperWire Advance® Coronary Guide Wire with Flex Tip (ViperWire Advance with Flex Tip).
Jan 13, 2021 07:00 am ET
Cardiovascular Systems, Inc. to Webcast Fiscal 2021 Second-Quarter Earnings Conference Call Wednesday, February 3
Cardiovascular Systems, Inc. (CSI®) (NASDAQ: CSII) will host a live webcast of its fiscal 2021 second-quarter conference call on Wednesday, February 3, 2021, at 3:30 p.m. CT (4:30 p.m. ET). CSI management will discuss results for its fiscal second quarter ended December 31, 2020, and its financial outlook. CSI will issue a post-market earnings release prior to the call on February 3, 2021.
Jan 04, 2021 04:05 pm ET
Cardiovascular Systems, Inc. to Present at the 23rd Annual Needham Virtual Growth Conference
On Wednesday, January 13, 2021, Cardiovascular Systems’ (NASDAQ: CSII) Chairman, President and Chief Executive Officer, Scott Ward, will participate in a fireside chat presentation at the 23rd Annual Needham Virtual Growth Conference at 4:15 p.m. Eastern Time.
Nov 11, 2020 07:00 am ET
Cardiovascular Systems, Inc. to Present at the Stifel 2020 Virtual Healthcare Conference
On Wednesday, November 18, 2020, Cardiovascular Systems’ (NASDAQ: CSII) Chairman, President and Chief Executive Officer, Scott Ward, will present at the Stifel 2020 Virtual Healthcare Conference at 3:20 p.m. Eastern Time.
Nov 04, 2020 04:05 pm ET
Cardiovascular Systems, Inc. Reports Fiscal 2021 First-Quarter Financial Results
Cardiovascular Systems, Inc. (CSI®) (NASDAQ: CSII), a medical device company developing and commercializing innovative interventional treatment systems for patients with peripheral and coronary artery disease, today reported financial results for its fiscal first quarter, ended September 30, 2020.
Oct 21, 2020 07:00 am ET
Cardiovascular Systems, Inc. to Webcast Fiscal 2021 First-Quarter Earnings Conference Call Wednesday, November 4
Cardiovascular Systems, Inc. (CSI®) (NASDAQ: CSII) will host a live webcast of its fiscal 2021 first-quarter conference call on Wednesday, November 4, 2020, at 3:30 p.m. CT (4:30 p.m. ET). CSI management will discuss results for its fiscal first quarter ended September 30, 2020, and its financial outlook. CSI will issue a post-market earnings release prior to the call on November 4, 2020.
Oct 14, 2020 08:00 am ET
Large Study Demonstrates Exceptional Safety and High Procedural Success With Cardiovascular Systems’ Diamondback 360® Coronary Orbital Atherectomy System (OAS)
Cardiovascular Systems, Inc. (CSI®) (NASDAQ: CSII), a medical device company developing and commercializing innovative interventional treatment systems for patients with peripheral and coronary artery disease, announced today that results from a large retrospective observational study of coronary orbital atherectomy were released at
Oct 07, 2020 07:00 am ET
Cardiovascular Systems Announces Presentation of Data From Large Coronary Orbital Atherectomy Study at the TCT Connect 2020 Conference
Cardiovascular Systems, Inc. (CSI®) (NASDAQ: CSII), a medical device company developing and commercializing innovative interventional treatment systems for patients with peripheral and coronary artery disease, announced today that results from a large retrospective observational study of coronary orbital atherectomy will be released at
Aug 20, 2020 04:05 pm ET
Cardiovascular Systems, Inc. Announces Kelvin Womack Joins Board of Directors
Cardiovascular Systems, Inc. (CSI®) (NASDAQ: CSII), a medical device company developing and commercializing innovative interventional treatment systems for patients with peripheral and coronary artery disease, today announced the addition of independent board member Kelvin Womack.
Aug 04, 2020 04:05 pm ET
Cardiovascular Systems, Inc. Reports Fiscal 2020 Fourth-Quarter Financial Results
Cardiovascular Systems, Inc. (CSI®) (NASDAQ: CSII), a medical device company developing and commercializing innovative interventional treatment systems for patients with peripheral and coronary artery disease, today reported financial results for its fiscal fourth quarter, ended June 30, 2020.
Jul 27, 2020 04:05 pm ET
Cardiovascular Systems Presents REACH PVI Study at the New Cardiovascular Horizons Conference
Cardiovascular Systems, Inc. (CSI®) (NASDAQ: CSII), a medical device company developing and commercializing innovative interventional treatment systems for patients with peripheral and coronary artery disease, today announced that the results from its REACH PVI study were presented at the New Cardiovascular Horizons (NCVH) Conference. This study prospectively evaluated acute clinical outcomes of orbital atherectomy via transradial access for the treatment of peripheral artery disease (PAD) in lower extremity lesions.
Jul 14, 2020 07:00 am ET
Cardiovascular Systems, Inc. to Webcast Fiscal 2020 Fourth-Quarter Earnings Conference Call Tuesday, August 4
Cardiovascular Systems, Inc. (CSI®) (NASDAQ: CSII) will host a live webcast of its fiscal 2020 fourth-quarter conference call on Tuesday, August 4, 2020, at 3:30 p.m. CT (4:30 p.m. ET). CSI management will discuss results for its fiscal fourth quarter ended June 30, 2020, and its financial outlook. CSI will issue a post-market earnings release prior to the call on August 4, 2020.
Jun 18, 2020 08:40 am ET
Cardiovascular Systems Announces Exercise of Underwriters’ Option
Cardiovascular Systems, Inc. (CSI) (Nasdaq: CSII), a medical device company developing and commercializing innovative interventional treatment systems for patients with peripheral and coronary artery disease, today announced that the underwriters of its recent public offering of common stock have fully exercised their option resulting in the issuance of an additional 551,470 shares. The option was granted in connection with the public offering of 3,676,471 shares of its common stock at a price to the public of $34.00 per share, which closed on June 12, 2020.
Jun 11, 2020 04:05 pm ET
Cardiovascular Systems, Inc. to Present at the Raymond James Human Health Innovation Conference
Cardiovascular Systems, Inc. (CSI®) (NASDAQ: CSII), a medical device company developing and commercializing innovative interventional treatment systems for patients with peripheral and coronary artery disease, today announced that Chairman, President and Chief Executive Officer, Scott Ward, will present at the Raymond James Human Health Innovation Conference on Thursday, June 18 at 1:40 p.m. Eastern Time.
Jun 09, 2020 10:32 pm ET
Cardiovascular Systems Prices Public Offering of Common Stock
Cardiovascular Systems, Inc. (CSI) (Nasdaq: CSII), a medical device company developing and commercializing innovative interventional treatment systems for patients with peripheral and coronary artery disease, today announced the pricing of its previously announced underwritten public offering of 3,676,471 shares of its common stock at a price to the public of $34.00 per share. Gross proceeds to CSI from the offering are expected to be approximately $125.0 million, before deducting underwriting discounts and commissions and offering expenses. In connection with the offering, CSI has granted to
Jun 09, 2020 04:09 pm ET
Cardiovascular Systems Announces Proposed Public Offering of Common Stock
Cardiovascular Systems, Inc. (CSI) (Nasdaq: CSII), a medical device company developing and commercializing innovative interventional treatment systems for patients with peripheral and coronary artery disease, today announced that it has commenced an underwritten public offering of $125 million of shares of common stock. In connection with this offering, CSI expects to grant the underwriters of the offering a 30-day option to purchase up to an additional 15% of the shares of common stock offered in the public offering. All of the shares in the offering will be sold by CSI. The offering is subje
May 05, 2020 04:05 pm ET
Cardiovascular Systems, Inc. Reports Fiscal 2020 Third-Quarter Financial Results
Cardiovascular Systems, Inc. (CSI®) (NASDAQ: CSII), a medical device company developing and commercializing innovative interventional treatment systems for patients with peripheral and coronary artery disease, today reported financial results for its fiscal third quarter, ended March 31, 2020.
Apr 21, 2020 07:00 am ET
 Cardiovascular Systems, Inc. to Webcast Fiscal 2020 Third-Quarter Earnings Conference Call Tuesday, May 5
Cardiovascular Systems, Inc. (CSI®) (NASDAQ: CSII) will host a live webcast of its fiscal 2020 third-quarter conference call on Tuesday, May 5, 2020, at 3:30 p.m. CT (4:30 p.m. ET). CSI management will discuss results for its fiscal third quarter ended March 31, 2020, and its financial outlook. CSI will issue a post-market earnings release prior to the call on May 5, 2020.
Feb 20, 2020 08:00 am ET
Beta Bionics Appoints Martha Aronson and Sean Carney to Its Board as Independent Directors
Beta Bionics, Inc. — a medical technology company developing and aiming to commercialize the world’s first fully automated bionic pancreas system called the iLet® today announced that Martha G. Aronson and Sean D. Carney have been appointed to the...
Feb 18, 2020 05:00 pm ET
Cardiovascular Systems, Inc. to Participate at Three Upcoming Investor Conferences
Cardiovascular Systems, Inc. (CSI®) (NASDAQ: CSII), a medical device company developing and commercializing innovative interventional treatment systems for patients with peripheral and coronary artery disease, today announced that management plans to present and host investor meetings at three upcoming conferences. Webcasts of each of the presentations will be made available on CSI’s website at
Feb 05, 2020 04:05 pm ET
Cardiovascular Systems, Inc. Reports Fiscal 2020 Second-Quarter Financial Results
Cardiovascular Systems, Inc. (CSI®) (NASDAQ: CSII), a medical device company developing and commercializing innovative interventional treatment systems for patients with peripheral and coronary artery disease, today reported financial results for its fiscal second quarter, ended December 31, 2019.
Jan 15, 2020 07:00 am ET
Cardiovascular Systems, Inc. to Webcast Fiscal 2020 Second-Quarter Earnings Conference Call Wednesday, February 5
Cardiovascular Systems, Inc. (CSI®) (NASDAQ: CSII) will host a live webcast of its fiscal 2020 second-quarter conference call on Wednesday, February 5, 2020, at 3:30 p.m. CT (4:30 p.m. ET). CSI management will discuss results for its fiscal second quarter ended December 31, 2019, and its financial outlook. CSI will issue a post-market earnings release prior to the call on February 5, 2020.
Dec 16, 2019 07:00 am ET
Cardiovascular Systems, Inc. Introduces Peripheral Orbital Atherectomy System With GlideAssist® in Europe
Cardiovascular Systems, Inc. (CSI®) (NASDAQ: CSII), a medical device company developing and commercializing innovative interventional treatment systems for patients with peripheral and coronary artery disease, announced today that the first patient in Europe has been treated with its Stealth 360® Peripheral Orbital Atherectomy System (OAS) 1.25mm Micro Crown with GlideAssist® (1.25 Micro Crown).
Nov 12, 2019 05:00 pm ET
Cardiovascular Systems, Inc. Announces Stephen Stenbeck Joins Board of Directors
Cardiovascular Systems, Inc. (CSI®) (NASDAQ: CSII), a medical device company developing and commercializing innovative interventional treatment systems for patients with peripheral and coronary artery disease, today announced the addition of independent board member Stephen Stenbeck. He replaces independent director Brent Blackey, who is retiring after 12 years of service.
Nov 05, 2019 07:00 am ET
Cardiovascular Systems, Inc. to Present at the Stifel 2019 Healthcare Conference
Cardiovascular Systems, Inc. (CSI®) (NASDAQ: CSII), a medical device company developing and commercializing innovative interventional treatment systems for patients with peripheral and coronary artery disease, today announced that management will present and host investor meetings at the Stifel 2019 Healthcare Conference on Tuesday, November 19, 2019.
Oct 29, 2019 04:05 pm ET
Cardiovascular Systems, Inc. Reports Fiscal 2020 First-Quarter Financial Results
Cardiovascular Systems, Inc. (CSI®) (NASDAQ: CSII), a medical device company developing and commercializing innovative interventional treatment systems for patients with peripheral and coronary artery disease, today reported financial results for its fiscal first quarter, ended September 30, 2019.
Oct 08, 2019 04:05 pm ET
First Patient in Middle East Treated With Cardiovascular Systems, Inc. Peripheral Orbital Atherectomy System
Cardiovascular Systems, Inc. (CSI®) (NASDAQ: CSII), a medical device company developing and commercializing innovative interventional treatment systems for patients with peripheral and coronary artery disease, announced today that the first patient in the United Arab Emirates has been treated with its Stealth 360® Peripheral Orbital Atherectomy System (OAS).
Oct 08, 2019 07:00 am ET
Cardiovascular Systems, Inc. to Webcast Fiscal 2020 First-Quarter Earnings Conference Call Tuesday, October 29
Cardiovascular Systems, Inc. (CSI®) (NASDAQ: CSII) will host a live webcast of its fiscal 2020 first-quarter conference call on Tuesday, October 29, 2019, at 3:30 p.m. CT (4:30 p.m. ET). CSI management will discuss results for its fiscal first quarter ended September 30, 2019, and its financial outlook. The company will issue a post-market earnings release prior to the call on October 29, 2019.
Sep 24, 2019 07:00 am ET
Cardiovascular Systems, Inc. Announces FDA Approval of the Coronary ViperWire Advance® With Flex Tip
Cardiovascular Systems, Inc. (CSI) (NASDAQ: CSII), a medical device company developing and commercializing innovative interventional treatment systems for patients with peripheral and coronary artery disease, today announced U.S. Food and Drug Administration (FDA) PMA approval of the new ViperWire Advance® Coronary Guide Wire with Flex Tip (ViperWire Advance with Flex Tip).
Aug 28, 2019 07:00 am ET
Cardiovascular Systems, Inc. to Participate at Three September Investor Conferences
Cardiovascular Systems, Inc. (CSI®) (NASDAQ: CSII), a medical device company developing and commercializing innovative interventional treatment systems for patients with peripheral and coronary artery disease, today announced that management will participate and host investor meetings at the following three conferences:
Aug 16, 2019 04:45 pm ET
Cardiovascular Systems Presents LIBERTY 360° Three-Year Outcomes at 2019 Amputation Prevention Symposium
Cardiovascular Systems, Inc. (CSI®) (NASDAQ: CSII), a medical device company developing and commercializing innovative interventional treatment systems for patients with peripheral and coronary artery disease (PAD and CAD), presented three-year outcomes from its LIBERTY 360° study in a late-breaking presentation at the 2019 Amputation Prevention Symposium (AMP) in Chicago.
Aug 12, 2019 04:05 pm ET
Cardiovascular Systems, Inc. to Feature LIBERTY 360° Three-year Outcomes Data at 2019 Amputation Prevention Symposium
Cardiovascular Systems, Inc. (CSI®) (NASDAQ: CSII), a medical device company developing and commercializing innovative interventional treatment systems for patients with peripheral and coronary artery disease, today announced that the three-year outcomes from its LIBERTY 360° study will be featured in a late-breaking presentation at the 2019 Amputation Prevention Symposium (AMP) in Chicago on Friday, August 16th. In addition, the two-year endovascular PAD-related health care costs in LIBERTY 360° and an orbital atherectomy economic sub-analysis will also be present
Aug 07, 2019 07:00 am ET
Cardiovascular Systems, Inc. to Participate in 8th Annual Intellisight Investor Conference on August 14
Cardiovascular Systems, Inc. (CSI®) (NASDAQ: CSII), a medical device company developing and commercializing innovative interventional treatment systems for patients with peripheral and coronary artery disease, today announced that management will present and host investor meetings at the 8th Annual Intellisight Conference in Minneapolis, Minn. on Wednesday, August 14th at 7:30 a.m. Central Time.
Aug 06, 2019 04:05 pm ET
Cardiovascular Systems, Inc. Reports Fiscal 2019 Fourth-Quarter Financial Results
Cardiovascular Systems, Inc. (CSI®) (NASDAQ: CSII), a medical device company developing and commercializing innovative interventional treatment systems for patients with peripheral and coronary artery disease, today reported financial results for its fiscal fourth quarter, ended June 30, 2019.
Aug 05, 2019 07:00 pm ET
Cardiovascular Systems, Inc. Acquires Gardia Medical Ltd.'s WIRION™ Embolic Protection System
Cardiovascular Systems, Inc. (CSI®) (NASDAQ: CSII), a medical device company developing and commercializing innovative interventional treatment systems for patients with peripheral and coronary artery disease, announced today that it has acquired the WIRION Embolic Protection System and related assets from Gardia Medical Ltd., a wholly owned Israeli subsidiary of Allium Medical Solutions Ltd. (TASE: ALMD).
Jul 25, 2019 04:05 pm ET
Cardiovascular Systems, Inc. Announces Former U.S. Congressman Erik Paulsen Joins Board of Directors
Cardiovascular Systems, Inc. (CSI®) (NASDAQ: CSII), a medical device company developing and commercializing innovative interventional treatment systems for patients with peripheral and coronary artery disease, today announced the addition of independent board member Erik Paulsen. He replaces director Scott Bartos, who is retiring from the board after seven years of service. The CSI board continues to have seven directors, six of whom are independent.
Jul 16, 2019 07:00 am ET
Cardiovascular Systems, Inc. to Webcast Fiscal 2019 Fourth-Quarter Earnings Conference Call Tuesday, August 6
Cardiovascular Systems, Inc. (CSI®) (NASDAQ: CSII) will host a live webcast of its fiscal 2019 fourth-quarter conference call on Tuesday, August 6, 2019, at 3:30 p.m. CT (4:30 p.m. ET). CSI management will discuss results for its fiscal fourth quarter ended June 30, 2019, and its financial outlook. The company will issue a post-market earnings release prior to the call on August 6, 2019.
Jun 11, 2019 05:00 pm ET
Cardiovascular Systems, Inc. Announces First Patient Enrolled in REACH PVI Clinical Study
Cardiovascular Systems, Inc. (CSI®) (NASDAQ: CSII), a medical device company developing and commercializing innovative interventional treatment systems for patients with peripheral and coronary artery disease, announced today the first patient was enrolled in the REACH PVI study. The purpose of this study is to prospectively evaluate acute clinical outcomes of orbital atherectomy via transradial access for the treatment of peripheral artery disease (PAD) in lower extremity lesions.
Jun 11, 2019 06:00 am ET
Cardiovascular Systems, Inc. to Present at the Raymond James Life Sciences & MedTech Conference
On Tuesday, June 18, 2019, Cardiovascular Systems’ (NASDAQ: CSII) Chairman, President and Chief Executive Officer, Scott Ward, will present at the Raymond James Life Sciences & MedTech Conference at 9:45 a.m. Eastern Time.
May 01, 2019 04:05 pm ET
Cardiovascular Systems, Inc. Reports Fiscal 2019 Third-Quarter Financial Results
Cardiovascular Systems, Inc. (CSI®) (NASDAQ: CSII), a medical device company developing and commercializing innovative interventional treatment systems for patients with peripheral and coronary artery disease, today reported financial results for its fiscal third quarter, ended March 31, 2019.
Apr 15, 2019 08:00 am ET
Report: Developing Opportunities within Toyota Motor, Red Hat, Koninklijke Philips N.V, Cardiovascular, SAP SE, and Pacific Ethanol — Future Expectations, Projections Moving into 2019
In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of Toyota Motor Corporation (NYSE:TM), Red Hat, Inc. (NYSE:RHT),...
Apr 10, 2019 07:00 am ET
Cardiovascular Systems, Inc. to Webcast Fiscal 2019 Third-Quarter Earnings Conference Call Wednesday, May 1
Cardiovascular Systems, Inc. (CSI®) (NASDAQ: CSII) will host a live webcast of its fiscal 2019 third-quarter conference call on Wednesday, May 1, 2019, at 3:30 p.m. CT (4:30 p.m. ET). CSI management will discuss results for its fiscal third quarter ended March 31, 2019, and its financial outlook. The company will issue a post-market earnings release prior to the call on May 1, 2019.
Mar 04, 2019 04:05 pm ET
Cardiovascular Systems, Inc. to Present at Three Upcoming Investor Conferences
Cardiovascular Systems, Inc. (CSI®) (NASDAQ: CSII), a medical device company developing and commercializing innovative interventional treatment systems for patients with peripheral and coronary artery disease, today announced that management will present and host investor meetings at the following three conferences:
Mar 01, 2019 04:55 pm ET
Washington Real Estate Investment Trust and Cardiovascular Systems Set to Join S&P SmallCap 600
NEW YORK, March 1, 2019 /PRNewswire/ -- S&P Dow Jones Indices will make the following changes to the S&P SmallCap 600:
Feb 20, 2019 07:00 am ET
Cardiovascular Systems, Inc. to Present at the 8th Annual SVB Leerink Global Healthcare Conference
On Wednesday, February 27, 2019, Cardiovascular Systems’ (NASDAQ: CSII) Chairman, President and Chief Executive Officer, Scott Ward, and Chief Operating Officer, Rhonda Robb, will present at the 8th Annual SVB Leerink Global Healthcare Conference at 3:00 p.m. Eastern Time.
Feb 19, 2019 08:10 am ET
New Research: Key Drivers of Growth for Omega Healthcare Investors, Cinedigm, Cardiovascular, Allegiant Travel, Catalyst Biosciences, and ESCO Technologies — Factors of Influence, Major Initiatives an
In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of Omega Healthcare Investors, Inc. (NYSE:OHI), Cinedigm Corp...
Jan 30, 2019 04:05 pm ET
Cardiovascular Systems, Inc. Reports Fiscal 2019 Second-Quarter Financial Results
Cardiovascular Systems, Inc. (CSI®) (NASDAQ: CSII), a medical device company developing and commercializing innovative interventional treatment systems for patients with peripheral and coronary artery disease, today reported financial results for its fiscal second quarter, ended December 31, 2018.
Jan 16, 2019 04:05 pm ET
First Patients in the Middle East Treated with Cardiovascular Systems, Inc. Diamondback 360® Coronary Orbital Atherectomy System
Cardiovascular Systems, Inc. (CSI®) (NASDAQ: CSII), a medical device company developing and commercializing innovative interventional treatment systems for patients with peripheral and coronary artery disease, announced today that the first patients in the United Arab Emirates (UAE) have been treated with its Diamondback 360® Coronary Orbital Atherectomy System (OAS).
Jan 07, 2019 07:00 am ET
Cardiovascular Systems, Inc. Announces Preliminary Fiscal 2019 Second-Quarter Revenues of $60.2 Million
Cardiovascular Systems, Inc. (CSI®) (NASDAQ: CSII), a medical device company developing and commercializing innovative interventional treatment systems for patients with peripheral and coronary artery disease, today announced preliminary and unaudited revenue results for its fiscal second quarter, ended December 31, 2018.
Jan 02, 2019 07:00 am ET
Cardiovascular Systems, Inc. Receives Approval for the Diamondback 360® Coronary Orbital Atherectomy System with Classic Crown and New ViperWire Advance® FlexTip Guidewire in Japan
Cardiovascular Systems, Inc. (CSI®) (NASDAQ: CSII), a medical device company developing and commercializing innovative interventional treatment systems for patients with peripheral and coronary artery disease, announced today that Japan’s Ministry of Health, Labor and Welfare (MHLW) has approved the Diamondback 360® Coronary Orbital Atherectomy System (OAS) with Classic Crown (Classic Crown) and ViperWire Advance® Coronary Guidewire FlexTip (FlexTip).
Dec 26, 2018 04:05 pm ET
Cardiovascular Systems, Inc. Announces First Patients Treated in United States with OrbusNeich Teleport® Microcatheter
Cardiovascular Systems, Inc. (CSI®) (NASDAQ: CSII), a medical device company developing and commercializing innovative interventional treatment systems for patients with peripheral and coronary artery disease, today announced that the first patients in the United States were treated using the OrbusNeich® Teleport Microcatheter (Teleport), which recently received U.S. Food and Drug Administration (FDA) 510(k) clearance.
Nov 28, 2018 07:50 am ET
Analysis: Positioning to Benefit within Cardiovascular, Ennis, Sparton, LightPath Technologies, Blue Apron, and HFF — Research Highlights Growth, Revenue, and Consolidated Results
In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Cardiovascular Systems, Inc. (NASDAQ:CSII), Ennis, Inc. (NYSE:EBF),...
Nov 13, 2018 04:05 pm ET
First Patients in Europe Treated with Cardiovascular Systems, Inc. Peripheral Orbital Atherectomy System
Cardiovascular Systems, Inc. (CSI®) (NASDAQ: CSII), a medical device company developing and commercializing innovative interventional treatment systems for patients with peripheral and coronary artery disease, announced today that the first patients in Germany have been treated with its Stealth 360® Peripheral Orbital Atherectomy System (OAS). The German cases represent the first commercial use of Peripheral OAS in Europe.
Nov 08, 2018 07:00 am ET
First Patient in Hong Kong Treated with Cardiovascular Systems, Inc. Coronary Orbital Atherectomy System
Cardiovascular Systems, Inc. (CSI®) (NASDAQ: CSII), a medical device company developing and commercializing innovative interventional treatment systems for patients with peripheral and coronary artery disease, announced today that the first patient in Hong Kong has been treated with its Diamondback 360® Coronary Orbital Atherectomy System (OAS). This procedure marks the first international coronary procedure taking place as a result of the company’s distribution agreement with OrbusNeich®.
Oct 30, 2018 04:05 pm ET
Cardiovascular Systems, Inc. Reports Fiscal 2019 First-Quarter Financial Results
Cardiovascular Systems, Inc. (CSI®) (NASDAQ: CSII), a medical device company developing and commercializing innovative interventional treatment systems for peripheral and coronary artery disease, today reported financial results for its fiscal first quarter, ended September 30, 2018.
Oct 18, 2018 08:00 am ET
Report: Exploring Fundamental Drivers Behind Continental Building Products, Hornbeck Offshore Services, Digi International, Triple-S Management, Collegium Pharmaceutical, and Cardiovascular — New Hori
In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Continental Building Products, Inc. (NYSE:CBPX), Hornbeck Offshore...
Oct 09, 2018 07:00 am ET
Cardiovascular Systems, Inc. to Webcast Fiscal 2019 First-Quarter Earnings Conference Call Tuesday, October 30
Cardiovascular Systems, Inc. (CSI®) (NASDAQ: CSII) will host a live webcast of its fiscal 2019 first-quarter conference call on Tuesday, October 30, 2019, at 3:45 p.m. CT (4:45 p.m. ET). CSI management will discuss results for its fiscal first quarter ended September 30, 2018, and its financial outlook. The company will issue a post-market earnings release prior to the call on October 30, 2018.
Sep 19, 2018 01:30 pm ET
Cardiovascular Systems, Inc. Announces First Commercial Launch of Peripheral Orbital Atherectomy System Outside the United States
Cardiovascular Systems, Inc. (CSI®) (NASDAQ: CSII), a medical device company developing and commercializing innovative interventional treatment systems for patients with peripheral and coronary artery disease, announced today that the first patient in Hong Kong has been treated with its Stealth 360® Peripheral Orbital Atherectomy System (OAS). The Hong Kong case is the first commercial use of Peripheral OAS outside of the United States.
Aug 24, 2018 08:15 am ET
Investor Expectations to Drive Momentum within ADTRAN, GMS, Brightcove, HFF, Imperva, and Cardiovascular — Discovering Underlying Factors of Influence
In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of ADTRAN, Inc. (NASDAQ:ADTN), GMS Inc. (NYSE:GMS), Brightcove Inc....
Aug 08, 2018 04:05 pm ET
Cardiovascular Systems Presents Liberty 360° Two-Year Outcomes at 2018 Amputation Prevention Symposium
Cardiovascular Systems, Inc. (CSI®) (NASDAQ: CSII), a medical device company developing and commercializing innovative interventional treatment systems for patients with peripheral and coronary artery disease, presented two-year outcomes from its LIBERTY 360° study in a late-breaking presentation at the 2018 Amputation Prevention Symposium (AMP) in Chicago.
Jul 31, 2018 08:00 am ET
Cardiovascular Systems, Inc. and Aerolase Corp. Sign Collaborative Agreement for Laser Atherectomy Technology
Cardiovascular Systems, Inc. (CSI®) (NASDAQ: CSII), a medical device company developing and commercializing innovative interventional treatment systems for patients with peripheral and coronary artery disease, today announced that it has signed an agreement with Aerolase Corp. (Aerolase®) to co-develop a new laser atherectomy device for physicians to use in more effectively treating multiple forms of arterial disease.
Jul 30, 2018 04:05 pm ET
Cardiovascular Systems, Inc. Reports Fiscal 2018 Fourth-Quarter Financial Results
Cardiovascular Systems, Inc. (CSI®) (NASDAQ: CSII), a medical device company developing and commercializing innovative interventional treatment systems for peripheral and coronary artery disease, today reported financial results for its fiscal fourth quarter, ended June 30, 2018.
Jul 16, 2018 04:05 pm ET
Cardiovascular Systems, Inc. Signs International Distribution Agreement with OrbusNeich
Cardiovascular Systems, Inc. (CSI®) (NASDAQ: CSII) has signed an exclusive international distribution agreement with OrbusNeich to sell its coronary and peripheral Orbital Atherectomy Systems (OAS) outside the United States and Japan. OrbusNeich manufactures and sells an extensive portfolio of coronary and peripheral products including stents, balloons and microcatheters. The company operates 12 regional sales offices throughout the world and their products are currently sold in over 60 countries.
Jul 10, 2018 07:00 am ET
Cardiovascular Systems, Inc. to Release Fiscal 2018 Fourth-Quarter Results on July 30
Cardiovascular Systems, Inc. (CSI®) (NASDAQ: CSII) will release fourth-quarter results on July 30 after market close. In lieu of hosting a quarterly earnings conference call, CSI management will discuss fourth-quarter results at the beginning of its analyst day on July 31. The analyst day webcast will begin on Tuesday, July 31, 2018, at 8:00 a.m. CT (9:00 a.m. ET).
Jun 19, 2018 07:45 am ET
Detailed Research: Economic Perspectives on LSC Communications, Cardiovascular, RPX, Nustar Energy, LSB Industries, and Digi International — What Drives Growth in Today's Competitive Landscape
In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of LSC Communications (NYSE:LKSD), Cardiovascular Systems, Inc....
May 02, 2018 04:05 pm ET
Cardiovascular Systems, Inc. Reports Fiscal 2018 Third-Quarter Financial Results
Cardiovascular Systems, Inc. (CSI®) (NASDAQ: CSII), a medical device company developing and commercializing innovative interventional treatment systems for peripheral and coronary artery disease, today reported financial results for its fiscal third quarter, ended March 31, 2018.
Apr 24, 2018 07:55 am ET
Research Report Identifies Spartan Motors, Cardiovascular, Stone Energy, Verisk Analytics, National Bank, and Sonoco Products with Renewed Outlook — Fundamental Analysis, Calculating Forward Movement
NEW YORK, April 24, 2018 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Spartan Motors, Inc. (NASDAQ:SPAR), Cardiovascular Systems,...
Apr 11, 2018 04:05 pm ET
Cardiovascular Systems, Inc. to Webcast Fiscal 2018 Third-Quarter Earnings Conference Call Wednesday, May 2
Cardiovascular Systems, Inc. (CSI®) (NASDAQ: CSII) will host a live webcast of its fiscal 2018 third-quarter conference call on Wednesday, May 2, 2018, at 3:45 p.m. CT (4:45 p.m. ET). CSI management will discuss results for its fiscal third quarter ended March 31, 2018, and its financial outlook. The company will issue a post-market earnings release prior to the call on May 2.
Mar 06, 2018 04:05 pm ET
Cardiovascular Systems Presents LIBERTY 360° 18-Month Outcomes at CRT18 Interventional Cardiology Conference
Cardiovascular Systems, Inc. (CSI®) (NASDAQ: CSII) a medical device company developing and commercializing innovative interventional treatment systems for patients with peripheral and coronary artery disease, presented 18-month outcomes from its LIBERTY 360° study at the Cardiovascular Research Technologies (CRT) 2018 interventional cardiology conference in Washington, D.C. The study evaluates the acute and long-term clinical and economic outcomes of endovascular device interventions, including CSI’s orbital atherectomy
Mar 01, 2018 02:31 pm ET
Cardiovascular Systems, Inc. and OrbusNeich Announce FDA Clearance of the First and Only 1.0mm Coronary Balloon in the U.S.
Cardiovascular Systems, Inc. (CSI®) (NASDAQ: CSII), a medical device company developing and commercializing innovative interventional treatment systems for patients with peripheral and coronary artery disease, today announced that the U.S. Food and Drug Administration (FDA) has granted 510(k) clearance for the OrbusNeich® 1.0mm Sapphire® II PRO coronary balloon.
Mar 01, 2018 07:55 am ET
Report: Developing Opportunities within Main Street Capital, United States Cellular, FibroGen, Cardiovascular, CDW, and ANSYS — Future Expectations, Projections Moving into 2018
NEW YORK, March 01, 2018 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Main Street Capital Corporation (NYSE:MAIN), United...
Feb 14, 2018 07:00 am ET
Cardiovascular Systems, Inc. Announces First Patients Treated from Radial Access Using Its Diamondback 360® Extended Length Peripheral Orbital Atherectomy Device
Cardiovascular Systems, Inc. (CSI®) (NASDAQ: CSII), a medical device company developing and commercializing innovative interventional treatment systems for peripheral and coronary artery disease, announced today that the first patients were treated using its FDA-cleared extended length Diamondback 360® Peripheral Orbital Atherectomy Device (OAD) to treat peripheral artery disease (PAD). Dr. Mahir Elder, an interventional cardiologist at the Detroit Medical Center Heart Hospital, and Drs. Ian Cawich and Vasili Lendel,
Feb 07, 2018 04:06 pm ET
Cardiovascular Systems, Inc. Appoints Jeff Points as Chief Financial Officer
Cardiovascular Systems, Inc. (CSI) (NASDAQ: CSII) announced today that Jeff Points was named Chief Financial Officer (CFO), effective immediately. As part of a planned succession, Points succeeds Larry Betterley as CFO and will report to Scott Ward, Chairman, President and Chief Executive Officer.
Feb 07, 2018 04:05 pm ET
Cardiovascular Systems, Inc. Reports Fiscal 2018 Second-Quarter Financial Results
Cardiovascular Systems, Inc. (CSI) (NASDAQ: CSII), a medical device company developing and commercializing innovative interventional treatment systems for peripheral and coronary artery disease, today reported financial results for its fiscal second quarter, ended December 31, 2017.
Feb 07, 2018 12:45 pm ET
Cardiovascular Systems, Inc. to Host Earnings Call
NEW YORK, NY / ACCESSWIRE / February 7, 2018 / Cardiovascular Systems, Inc. (NASDAQ: CSII) will be discussing their earnings results in their Q2 Earnings Call to be held on February 7, 2018 at 4:45 PM Eastern Time.
Feb 05, 2018 07:00 am ET
Cardiovascular Systems, Inc. to Present at the LEERINK Partners 7th Annual Global Healthcare Conference
On Wednesday, February 14, 2018, Cardiovascular Systems’ (NASDAQ: CSII) Chairman, President and Chief Executive Officer, Scott Ward, will present at the LEERINK Partners 7th Annual Global Healthcare Conference at 10:30 a.m. Eastern Time.
Feb 01, 2018 04:05 pm ET
Cardiovascular Systems, Inc. Announces Commercial Launch in Japan
Cardiovascular Systems, Inc. (CSI) (NASDAQ: CSII), a medical device company developing and commercializing innovative interventional treatment systems for patients with peripheral and coronary artery disease, announced today that it has commercially treated the first patient in Japan with its Diamondback 360® Coronary OAS Micro Crown (Micro Crown).
Jan 24, 2018 06:00 am ET
Cardiovascular Systems, Inc. Appoints Rhonda Robb as New Chief Operating Officer
Cardiovascular Systems, Inc. (CSI) (NASDAQ: CSII), a medical device company developing and commercializing innovative interventional treatment systems for peripheral and coronary artery disease, today announced that it has appointed Rhonda Robb as its new Chief Operating Officer. She will report to Scott Ward, CSI Chairman, President and Chief Executive Officer.
Jan 18, 2018 07:00 am ET
Cardiovascular Systems Expands Product Portfolio to Further Support Peripheral and Coronary Interventions
Cardiovascular Systems, Inc. (CSI) (NASDAQ: CSII), a medical device company developing and commercializing innovative interventional treatment systems for patients with peripheral and coronary artery disease, today announced two new partnerships broadening the company’s product portfolio. CSI is now the exclusive U.S. distributor of OrbusNeich balloon products. Additionally, the company has signed an original equipment manufacturer (OEM) agreement with Integer Holdings Corporation for CSI-branded ZILIENT™ guidewires.
Jan 10, 2018 07:00 am ET
Cardiovascular Systems to Webcast Fiscal 2018 Second-Quarter Earnings Conference Call Wednesday, February 7
Cardiovascular Systems, Inc. (CSI) (NASDAQ: CSII) will host a live webcast of its fiscal 2018 second-quarter conference call on Wednesday, February 7, 2018, at 3:45 p.m. CT (4:45 p.m. ET). Scott Ward, Chairman, President and Chief Executive Officer, and Larry Betterley, Chief Financial Officer, will discuss CSI’s results for its fiscal second quarter ended December 31, 2017, and its financial outlook. The company will issue a post-market earnings release prior to the call on February 7.
Jan 04, 2018 07:40 am ET
Report: Exploring Fundamental Drivers Behind K2M Group, Altra Industrial Motion, FibroGen, Cardiovascular, Bluerock Residential Growth REIT, and National Presto Industries — New Horizons, Emerging Tre
NEW YORK, Jan. 04, 2018 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of K2M Group Holdings, Inc. (NASDAQ:KTWO), Altra...
Nov 28, 2017 02:15 pm ET
Scott+Scott, Attorneys at Law, LLP is Investigating Derivative Claims on Behalf of Shareholders of Cardiovascular Systems, Inc. (CSII)
Scott+Scott, Attorneys at Law, LLP (“Scott+Scott”), a national shareholder and consumer rights litigation firm, reminds investors that it is investigating whether certain officers and directors of Cardiovascular Systems, Inc. (“Cardiovascular Systems” or the “Company”)
Oct 25, 2017 04:05 pm ET
Oct 12, 2017 01:27 pm ET
Scott+Scott, Attorneys at Law, LLP Is Investigating Derivative Claims on Behalf of Shareholders of Cardiovascular Systems, Inc. (CSII)
NEW YORK, Oct. 12, 2017 /PRNewswire/ -- Scott+Scott, Attorneys at Law, LLP ("Scott+Scott"), a national shareholder and consumer rights litigation firm, is investigating whether certain officers and directors of Cardiovascular Systems, Inc. ("Cardiovascular Systems" or the "Company") (NASDAQ: CSII) breached fiduciary duties owed to the Company and its shareholders.  If you are a Cardiovascular Systems shareholder, you are encouraged to contact a Scott+Scott attorney at (844) 818-6982 for additional information.
Oct 09, 2017 10:33 am ET
SHAREHOLDER ALERT: Purcell Julie & Lefkowitz LLP Is Investigating Cardiovascular Systems, Inc. for Potential Breaches Of Fiduciary Duty By Its Board of Directors
NEW YORK, Oct. 9, 2017 /PRNewswire/ -- Purcell Julie & Lefkowitz LLP, a class action law firm dedicated to representing shareholders nationwide, is investigating a potential breach of fiduciary duty claim involving the board of directors of Cardiovascular Systems, Inc. (NASDAQ: CSII).
Oct 04, 2017 01:16 pm ET
Scott+Scott, Attorneys at Law, LLP Is Investigating Derivative Claims on Behalf of Shareholders of Cardiovascular Systems, Inc. (CSII)
Scott+Scott, Attorneys at Law, LLP (“Scott+Scott”), a national shareholder and consumer rights litigation firm, is investigating whether certain officers and directors of Cardiovascular Systems, Inc. (“Cardiovascular Systems” or the “Company”) (NASDAQ: CSII) breached t
Oct 04, 2017 07:00 am ET
Cardiovascular Systems to Webcast Fiscal 2018 First-Quarter Earnings Conference Call Wednesday, October 25
Cardiovascular Systems, Inc. (CSI) (NASDAQ: CSII) will host a live webcast of its fiscal 2018 first-quarter conference call on Wednesday, October 25, 2017, at 3:45 p.m. CT (4:45 p.m. ET). Scott Ward, Chairman, President and Chief Executive Officer, and Larry Betterley, Chief Financial Officer, will discuss CSI’s results for its fiscal first quarter ended September 30, 2017, and its financial outlook. The company will issue a post-market earnings release prior to the call on October 25.
Apr 04, 2017 10:03 am ET
Cardiovascular Systems, Inc. Secures $40 Million Line of Credit from Silicon Valley Bank
ST. PAUL, Minn., April 4, 2017 /PRNewswire/ -- Cardiovascular Systems, Inc. (CSI) (NASDAQ: CSII), a medical device company developing and commercializing innovative solutions for treating peripheral and coronary vascular disease, has entered into a credit facility with Silicon Valley Bank (SVB), the bank of the world's most innovative companies and their investors. This agreement provides CSI with up to $40 million for working capital and general corporate purposes.
May 12, 2016 02:07 pm ET
Updated: Harwood Feffer LLP Announces Investigation of Cardiovascular Systems, Inc.
NEW YORK, May 12, 2016 /PRNewswire/ -- Harwood Feffer LLP (www.hfesq.com) is investigating potential claims against the board of directors of Cardiovascular Systems, Inc. ("CSII" or the "Company") (NASDAQ: CSII), concerning whether the board has breached its fiduciary duties to shareholders.
Apr 05, 2016 12:35 pm ET
Shareholder Alert: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses In Excess Of $100,000 Investing In Cardiovascular Systems Inc. To Contact The Firm Before Upcoming Lead Plaintiff Deadl
NEW YORK, April 5, 2016 /PRNewswire/ -- Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in Cardiovascular Systems Inc. ("Cardiovascular" or the "Company") (NASDAQ:CSII) of the April 12, 2016 deadline to seek the role of lead plaintiff in a federal securities class action lawsuit filed against the Company and certain officers.
Apr 04, 2016 09:00 am ET
Important Lead Plaintiff Deadline Reminder for Cardiovascular Systems Shareholders From Kessler Topaz Meltzer & Check, LLP
Kessler Topaz Meltzer & Check, LLP reminds Cardiovascular Systems, Inc. (NASDAQ: CSII) ("CSI" or the "Company") shareholders that a class action lawsuit has been filed in the United States District Court for the District of Minnesota on behalf...
Mar 22, 2016 11:59 am ET
INVESTOR ALERT: The Law Offices of Vincent Wong Notify Investors of Class Action Involving Cardiovascular Systems, Inc. and a Lead Plaintiff Deadline of April 12, 2016 - CSII
NEW YORK, March 22, 2016 /PRNewswire/ -- The Law Offices of Vincent Wong announce that a class action lawsuit has been commenced in the USDC for the Central District of California on behalf of investors who purchased Cardiovascular Systems, Inc. (NASDAQ: CSII) securities between September 12, 2011 and January 21, 2016.
Mar 04, 2016 04:13 pm ET
Kessler Topaz Meltzer & Check, LLP Files Shareholder Class Action Lawsuit Against Cardiovascular Systems, Inc. - CSII
RADNOR, Pa., March 4, 2016 /PRNewswire/ -- The law firm of Kessler Topaz Meltzer & Check, LLP announces that it has filed a shareholder class action lawsuit in the United States District Court for the District of Minnesota against Cardiovascular Systems, Inc. (NASDAQ: CSII) ("CSI" or the "Company") on behalf of purchasers of the Company's common stock between September 12, 2011 and January 21, 2016, inclusive (the "Class Period").
Feb 29, 2016 09:11 am ET
Law Offices of Marc S. Henzel Announces Investigation of Companies for Violations of the Federal Securities Laws
MERION, Pa., Feb. 29, 2016 /PRNewswire/ -- The Law Offices of Marc S. Henzel (www.henzellaw.com), a firm focusing on shareholder litigation, gives notice to shareholders of investigation into the following securities for violations of the Federal Securities Laws:
Feb 26, 2016 04:15 pm ET
Ryan & Maniskas, LLP Announces Class Action Lawsuit Against Cardiovascular Systems Inc.
WAYNE, Pa., Feb. 26, 2016 /PRNewswire/ -- Ryan & Maniskas, LLP announces that a class action lawsuit has been filed in United States District Court for the Central District of California on behalf of all persons or entities that purchased Cardiovascular Systems, Inc. (NASDAQ: CSII) ("CSI" or the "Company") securities between September 12, 2011 and January 21, 2016, inclusive (the "Class Period").
Feb 23, 2016 02:53 pm ET
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of Cardiovascular Systems, Inc. of Class Action Lawsuit and a Lead Plaintiff Deadline of April 12, 2016 -- CSII
The following statement is being issued by Levi & Korsinsky, LLP: To: All persons or entities who purchased or otherwise acquired securities of Cardiovascular Systems, Inc. ("Cardiovascular Systems") (NASDAQ: CSII) between September 12,...
Feb 19, 2016 01:04 pm ET
SHAREHOLDER ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses in Excess of $100,000 Investing in Cardiovascular Systems Inc. to Contact the Firm Before Lead Plaintiff Deadline
Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in Cardiovascular Systems Inc. ("Cardiovascular" or the "Company") (NASDAQ: CSII) of the April 12, 2016 deadline to seek the role of lead plaintiff in a federal...
Feb 18, 2016 06:39 pm ET
Shareholder Class Action Filed Against Cardiovascular Systems, Inc. - CSII
RADNOR, Pa., Feb. 18, 2016 /PRNewswire/ -- The law firm of Kessler Topaz Meltzer & Check, LLP announces that a shareholder class action lawsuit has been filed against Cardiovascular Systems, Inc. (NASDAQ: CSII) ("CSI" or the "Company") on behalf of purchasers of the Company's securities between September 12, 2011 and January 21, 2016, inclusive (the "Class Period").
Feb 18, 2016 06:35 pm ET
SHAREHOLDER ALERT: Law Office of Brodsky & Smith, LLC Announces Investigation of Cardiovascular Systems, Inc. - CSII
BALA CYNWYD, Pa., Feb. 18, 2016 /PRNewswire/ -- Law Office of Brodsky & Smith, LLC announces an investigation of Cardiovascular Systems, Inc ("Cardiovascular Systems" or the "Company") (Nasdaq -CSII- News) for potential violations of federal securities laws and breaches of the Cardiovascular Systems Board's fiduciary duties.
Feb 16, 2016 11:42 am ET
SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Notifies Investors of Class Action Against Cardiovascular Systems, Inc. (CSII) and Lead Plaintiff Deadline: April 12, 2016
NEW YORK, Feb. 16, 2016 /PRNewswire/ -- Bronstein, Gewirtz & Grossman, LLC, notifies investors of class action against Cardiovascular Systems, Inc. ("Cardiovascular Systems" or the "Company") (NASDAQ: CSII).  The class action has been filed on behalf of a class consisting of all persons or entities who purchased Cardiovascular Systems, Inc. securities during the period between September 12, 2011 and January 21, 2016 inclusive (the "Class Period"). 

Thank you for visiting InsiderTracking.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you wish to consider using a browser that blocks ads, please log in or subscribe.

Alternatively, if you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). If you are in private browsing mode and do not want to subscribe, please disable tracking protection while visiting our website.

Thank you for using Insider Tracking.